EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma

Yu-Hang Ye, Hao-Yang Xin, Jia-Li Li, Ning Li, Si-Yuan Pan, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Peng-Cheng Wang, Chu-Bin Luo, Rong-Qi Sun, Jia Fan und 3 weitere

Clinical and Molecular Hepatology · 01.10.2024 · 30 (4) · 914-928

DOI: 10.3350/cmh.2024.0296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2024. Verfasst von Yu-Hang Ye und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Actins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Shanghai Technical Standard Program, Shanghai Medical Innovation Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds/Aims: Intrahepatic cholangiocarcinoma (ICC) is a highly desmoplastic tumor with poor prognosis even after curative resection. We investigated the associations between the composition of the ICC stroma and immune cell infiltration and aimed to develop a stromal-immune signature to predict prognosis in surgically treated ICC.

Methods

We recruited 359 ICC patients and performed immunohistochemistry to detect α-smooth muscle actin (α-SMA), CD3, CD4, CD8, Foxp3, CD68, and CD66b. Aniline was used to stain collagen deposition. Survival analyses were performed to detect prognostic values of these markers. Recursive partitioning for a discrete-time survival tree was applied to define a stromal-immune signature with distinct prognostic value. We delineated an integrated stromal-immune signature based on immune cell subpopulations and stromal composition to distinguish subgroups with different recurrence-free survival (RFS) and overall survival (OS) time.

Results

We defined four major patterns of ICC stroma composition according to the distributions of α-SMA and collagen: dormant (α-SMAlow/collagenhigh), fibrogenic (α-SMAhigh/collagenhigh), inert (α-SMAlow/collagenlow), and fibrolytic (α-SMAhigh/collagenlow). The stroma types were characterized by distinct patterns of infiltration by immune cells. We divided patients into six classes. Class I, characterized by high CD8 expression and dormant stroma, displayed the longest RFS and OS, whereas Class VI, characterized by low CD8 expression and high CD66b expression, displayed the shortest RFS and OS. The integrated stromal-immune signature was consolidated in a validation cohort.

Conclusions

We developed and validated a stromal-immune signature to predict prognosis in surgically treated ICC. These findings provide new insights into the stromal-immune response to ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsActinsHumansFemaleMaleMiddle AgedPrognosisAgedStromal CellsBiomarkers, TumorAntigens, CDCell Adhesion MoleculesGPI-Linked ProteinsCollagenAdultTumor MicroenvironmentImmunohistochemistry

Stichwörter der Autor:innen

Immune cellIntrahepatic cholangiocarcinomaPrognosisStromal signature

Substanzen

ActinsBiomarkers, TumorACTA2 protein, humanAntigens, CDCell Adhesion MoleculesGPI-Linked ProteinsCollagenCEACAM8 protein, human

Autor:innen und Institutionen

  • Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Technical Standard Program
  • Shanghai Medical Innovation Research Project

Zitieren

APA

Ye, Y. H., Xin, H. Y., Li, J. L., Li, N., Pan, S. Y., Chen, L., Pan, J. Y., Hu, Z. Q., Wang, P. C., Luo, C. B., Sun, R. Q., Fan, J., Zhou, J., Zhou, Z. J., & Zhou, S. L. (2024). Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma. Clinical and Molecular Hepatology, 30(4), 914-928. https://doi.org/10.3350/cmh.2024.0296

Vancouver

Ye YH, Xin HY, Li JL, Li N, Pan SY, Chen L, et al. Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma. Clinical and Molecular Hepatology. 2024;30(4):914-928. doi:10.3350/cmh.2024.0296

BibTeX
@article{Ye2024,
  author = {Ye, Yu-Hang and Xin, Hao-Yang and Li, Jia-Li and Li, Ning and Pan, Si-Yuan and Chen, Long and Pan, Jing-Yue and Hu, Zhi-Qiang and Wang, Peng-Cheng and Luo, Chu-Bin and Sun, Rong-Qi and Fan, Jia and Zhou, Jian and Zhou, Zheng-Jun and Zhou, Shao-Lai},
  title = {Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  volume = {30},
  number = {4},
  pages = {914--928},
  doi = {10.3350/cmh.2024.0296}
}
Kostenlos starten →